• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis

byNeel MistryandTeddy Guo
September 14, 2023
in Chronic Disease, Pediatrics, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Time to disease flare was significantly shorter in the placebo group versus baricitinib.

2. There was no difference in serious adverse events between the baricitinib and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely affect an individual’s quality of life. First-line treatment for JIA includes nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic disease-modifying antirheumatic drugs (DMARDs), however, many patients with JIA continue to experience refractory symptoms. This randomized controlled trial aimed to assess the safety and efficacy of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo, in patients with refractory JIA. The primary outcome of this study was time to disease flare in the withdrawal period, while key secondary outcomes included the proportion of patients with a flare and change in the Juvenile Arthritis Disease Activity Score 27 (JADAS-27). According to study results, baricitinib was effective in reducing JIA flare rates in patients without increasing rates of serious adverse events among patients with JIA refractory to standard therapy. Although this study was well done, it was limited by a small follow-up period, thus affecting the validity of the findings.

Click to read the study in The Lancet

Relevant Reading: Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

RELATED REPORTS

Inebilizumab improves outcome in patients generalized myasthenia gravis

Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard

Evaluating scar outcomes in pediatric burn patients following skin grafting 

In-depth [randomized-controlled trial]: Between Dec 17, 2018, and Mar 3, 2021, 263 patients were screened for eligibility across 75 centres in 20 countries. Included were patients aged 2 to <18 years with various forms of JIA (polyarticular, extended oligoarticular, enthesitis-related, and juvenile psoriatic arthritis) refractory to standard treatments. Altogether, 220 patients were included in the final analysis. The primary outcome of time to disease flare was significantly longer in the baricitinib group versus placebo (not evaluable in baricitinib due to <50% flare event vs. 27.14 weeks in placebo, hazard ratio [HR] 0.241, 95% confidence interval [CI] 0.128-0.453, p<0.0001). Serious adverse events were comparable in the baricitinib and placebo groups (5% vs. 4%, incidence rate [IR] 9.7 vs. 10.2 per 100 patient-years at risk) with pulmonary embolism (1%, IR 2.4) in the baricitinib group being most common. Overall, findings from this study suggest that baricitinib may be effective for the treatment of refractory JIA and possesses a tolerable safety profile.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arthritisenthesitisenthesitis-related arthritisJIAjoint painjuvenile idiopathic arthritisjuvenile psoriatic arthritispediatric rheumatologypediatricspsoriatic arthritisrheumatologysystemic JIA
Previous Post

#VisualAbstract: Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events

Next Post

Low-grade inflammation scores can help predict 90-day outcomes after stroke

RelatedReports

Age and number of islet autoantibodies associated with diabetes risk
Neurology

Inebilizumab improves outcome in patients generalized myasthenia gravis

July 10, 2025
Baby-led weaning not linked to increased choking
AI Roundup

Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard

July 7, 2025
Pediatrics

Evaluating scar outcomes in pediatric burn patients following skin grafting 

June 26, 2025
Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

June 9, 2025
Next Post
Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Low-grade inflammation scores can help predict 90-day outcomes after stroke

#VisualAbstract: Prehospital Tranexamic Acid for Severe Trauma

#VisualAbstract: Prehospital Tranexamic Acid for Severe Trauma

Shared decision-making tool for antidepressants improves patient and physician satisfaction

Antidepressants are effective in patients with comorbid depression and medical diseases

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
  • Structured exercise intervention improves survival in colon cancer patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.